CHIMERIC HEPATITIS-B CORE ANTIGEN PARTICLES CONTAINING B-EPITOPES AND TH-EPITOPES OF HUMAN PAPILLOMAVIRUS TYPE-16 E7 PROTEIN INDUCE SPECIFIC ANTIBODY AND T-HELPER RESPONSES IN IMMUNIZED MICE

被引:39
作者
TINDLE, RW [1 ]
HERD, K [1 ]
LONDONO, P [1 ]
FERNANDO, GJP [1 ]
CHATFIELD, SN [1 ]
MALCOLM, K [1 ]
DOUGAN, G [1 ]
机构
[1] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND
关键词
D O I
10.1006/viro.1994.1217
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of hepatitis B core antigen (HBcAg) as an immunogenic delivery vehicle for foreign epitopes has been reported. Here we report the insertion of DNA sequences encoding immunodominant linear B-epitopes and a ''universal'' T-helper epitope of human papillomavirus (HPV) type 16 E7 transforming protein into the full-length HBcAg gene cloned into an inducible bacterial expression plasmid (pPN1.0). The resulting chimeric proteins assembled into particles which were highly immunogenic. Mice immunised with particles containing one or two of the three E7 B-epitopes under consideration produced strong epitope-specific antibody responses with both IgG and IgG2a components which recognised eukaryotic E7. T-proliferative responses were elicited to the E7 T-epitope as well as HBcAg T-epitope(s). Lymph node cells from immunised mice produced IL-2 and IL-4 when specifically recalled in vitro, indicating stimulation of both Th, and Th, helper cell compartments. Since HBcAg particles can be administered in adjuvant acceptable for human application and can elicit mucosal responses after nasal or oral immunisation, these results have implications for vaccine design in HPV16-associated anogenital cancer. (C) 1994 Academic Press, Inc.
引用
收藏
页码:547 / 557
页数:11
相关论文
共 31 条
  • [1] AROGS P, 1988, EMBO J, V7, P819
  • [2] FOREIGN EPITOPES IN IMMUNODOMINANT REGIONS OF HEPATITIS-B CORE PARTICLES ARE HIGHLY IMMUNOGENIC AND CONFORMATIONALLY RESTRICTED
    BROWN, AL
    FRANCIS, MJ
    HASTINGS, GZ
    PARRY, NR
    BARNETT, PV
    ROWLANDS, DJ
    CLARKE, BE
    [J]. VACCINE, 1991, 9 (08) : 595 - 601
  • [3] USE OF THE NIRB PROMOTER TO DIRECT THE STABLE EXPRESSION OF HETEROLOGOUS ANTIGENS IN SALMONELLA ORAL VACCINE STRAINS - DEVELOPMENT OF A SINGLE-DOSE ORAL TETANUS VACCINE
    CHATFIELD, SN
    CHARLES, IG
    MAKOFF, AJ
    OXER, MD
    DOUGAN, G
    PICKARD, D
    SLATER, D
    FAIRWEATHER, NF
    [J]. BIO-TECHNOLOGY, 1992, 10 (08): : 888 - 892
  • [4] HUMAN PAPILLOMAVIRUS TYPE-16 NUCLEOPROTEIN-E7 IS A TUMOR REJECTION ANTIGEN
    CHEN, LP
    THOMAS, EK
    HU, SL
    HELLSTROM, I
    HELLSTROM, KE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) : 110 - 114
  • [5] IMPROVED IMMUNOGENICITY OF A PEPTIDE EPITOPE AFTER FUSION TO HEPATITIS-B CORE PROTEIN
    CLARKE, BE
    NEWTON, SE
    CARROLL, AR
    FRANCIS, MJ
    APPLEYARD, G
    SYRED, AD
    HIGHFIELD, PE
    ROWLANDS, DJ
    BROWN, F
    [J]. NATURE, 1987, 330 (6146) : 381 - 384
  • [6] PRESENTATION AND IMMUNOGENICITY OF VIRAL EPITOPES ON THE SURFACE OF HYBRID HEPATITIS-B VIRUS CORE PARTICLES PRODUCED IN BACTERIA
    CLARKE, BE
    BROWN, AL
    GRACE, KG
    HASTINGS, GZ
    BROWN, F
    ROWLANDS, DJ
    FRANCIS, MJ
    [J]. JOURNAL OF GENERAL VIROLOGY, 1990, 71 : 1109 - 1117
  • [7] ALGAMMULIN (GAMMA-INULIN ALUM HYBRID ADJUVANT) HAS GREATER ADJUVANTICITY THAN ALUM FOR HEPATITIS-B SURFACE-ANTIGEN IN MICE
    COOPER, PD
    TURNER, R
    MCGOVERN, J
    [J]. IMMUNOLOGY LETTERS, 1991, 27 (02) : 131 - 134
  • [8] 2 NEWLY IDENTIFIED HUMAN PAPILLOMAVIRUS TYPES (HPV-40 AND 57) ISOLATED FROM MUCOSAL LESIONS
    DEVILLIERS, EM
    HIRSCHBEHNAM, A
    VONKNEBELDOEBERITZ, C
    NEUMANN, C
    ZURHAUSEN, H
    [J]. VIROLOGY, 1989, 171 (01) : 248 - 253
  • [9] DOTSIKA EN, 1987, IMMUNOLOGY, V62, P665
  • [10] IMMUNOLOGICAL PROPERTIES OF HEPATITIS-B CORE ANTIGEN FUSION PROTEINS
    FRANCIS, MJ
    HASTINGS, GZ
    BROWN, AL
    GRACE, KG
    ROWLANDS, DJ
    BROWN, F
    CLARKE, BE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) : 2545 - 2549